Yondelis Approved for the Treatment of Soft Tissue Sarcoma
October 23, 2015 – The U.S. Food and Drug Administration granted approval to Yondelis (trabectedin), manufactured by Janssen Biotech. Yondelis is a cytotoxic antitumor agent for the treatment of patients with unresectable or mestatic liposarcoma (LPS) or leiomyosarcoma (LMS) and prior treatment with an anthracycline containing regimen. Soft Tissue Sarcoma (STS) subtypes, LPS and LMS account for more than 35% of STS cases. The dosage recommended for Yondelis is 1.5mg/m2 body surface area as a 24-hour intravenous infusion every three weeks through a central venous line. It is advisable that patients be given dexamethasone 20mg IV, thirty minutes before each infusion. Janssen Biotech plans to launch Yondelis in mid-November.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.